How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/moderate-to-severe-alzheimer-s-type-dementia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Moderate to Severe Alzheimer's Type Dementia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Moderate to Severe Alzheimer's Type Dementia (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Moderate to Severe Alzheimer's Type Dementia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Namenda	MEMANTINE	AbbVie	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Aricept	DONEPEZIL	Eisai	Cholinesterase Inhibitor	Sigma non-opioid intracellular receptor 1	1996-01-01
Donepezil (Aricept)	Donepezil (Aricept)	University of Virginia	Acetylcholinesterase Inhibitor	Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon
Aricept	Aricept	Eisai Korea Inc.		Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon
Namenda	Namenda	Inova Health Care Services		Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 3A, Acetylcholinesterase
Ebixa	Ebixa	Konkuk University Medical Center		Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 3A, Acetylcholinesterase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AbbVie · 1 drug in Moderate to Severe Alzheimer's Type Dementia
Eisai · 1 drug in Moderate to Severe Alzheimer's Type Dementia
Eisai Korea Inc. · 1 drug in Moderate to Severe Alzheimer's Type Dementia
Inova Health Care Services · 1 drug in Moderate to Severe Alzheimer's Type Dementia
Konkuk University Medical Center · 1 drug in Moderate to Severe Alzheimer's Type Dementia
University of Virginia · 1 drug in Moderate to Severe Alzheimer's Type Dementia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Moderate to Severe Alzheimer's Type Dementia:

Cite this brief

Drug Landscape (2026). Moderate to Severe Alzheimer's Type Dementia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/moderate-to-severe-alzheimer-s-type-dementia. Accessed 2026-06-10.

Moderate to Severe Alzheimer's Type Dementia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing